Transverse Myelitis
18
3
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury
Biobank For MS And Other Demyelinating Diseases
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Serum Auto-Antibodies in Neurological Diseases
Home Based Tele-exercise for People With Chronic Neurological Impairments
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance
Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis
Clinical Trial of a Serious Game for Individuals With SCI/D
Central Pain Study for ABX-1431
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis